MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 522611 | Name: TBA-354
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TBA-354, also known as SN31354, is a potent anti-tuberculosis drug candidate. TBA-354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of PA-824. TBA-354 maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug-sensitive and drug-resistant isolates. TBA-354 is a promising next-generation nitroimidazole antitubercular agent.

Chemical Structure

TBA-354
TBA-354
CAS#1257426-19-9

Theoretical Analysis

MedKoo Cat#: 522611

Name: TBA-354

CAS#: 1257426-19-9

Chemical Formula: C19H15F3N4O5

Exact Mass: 436.0995

Molecular Weight: 436.35

Elemental Analysis: C, 52.30; H, 3.47; F, 13.06; N, 12.84; O, 18.33

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
100mg USD 450.00 2 Weeks
200mg USD 750.00 2 Weeks
500mg USD 1,550.00 2 Weeks
1g USD 2,450.00 2 Weeks
2g USD 4,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
TBA-354, TBA 354, TBA354, SN31354, SN-31354, SN 31354
IUPAC/Chemical Name
(S)-2-nitro-6-((6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
InChi Key
ZXSGSFMORAILEY-HNNXBMFYSA-N
InChi Code
InChI=1S/C19H15F3N4O5/c20-19(21,22)31-14-4-2-13(3-5-14)16-6-1-12(7-23-16)10-29-15-8-25-9-17(26(27)28)24-18(25)30-11-15/h1-7,9,15H,8,10-11H2/t15-/m0/s1
SMILES Code
O=[N+](C1=CN2C(OC[C@@H](OCC3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)N=C3)C2)=N1)[O-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 436.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lee J, You C, Kwon G, Noh J, Lee K, Kim K, Kang K, Kang K. Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma. Cell Death Dis. 2024 Nov 8;15(11):801. doi: 10.1038/s41419-024-07198-0. PMID: 39516467; PMCID: PMC11549485. 2: Geethadevi A, Raabe EH. Approaches for prevention of tumors in patients with rhabdoid tumor predisposition syndrome. Neurooncol Adv. 2024 Sep 12;6(1):vdae158. doi: 10.1093/noajnl/vdae158. PMID: 39434925; PMCID: PMC11491493. 3: Gold S, Shilatifard A. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges. J Clin Invest. 2024 Oct 15;134(20):e183391. doi: 10.1172/JCI183391. PMID: 39403928; PMCID: PMC11473148. 4: Kikuchi S, Nabe Y, Horaguchi R, Minemura T, Murakami J, Noguchi A, Takagi K, Kamihara Y, Wada A, Fujihira T, Sato T. Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase. Int Cancer Conf J. 2024 Aug 21;13(4):488-492. doi: 10.1007/s13691-024-00716-z. PMID: 39398919; PMCID: PMC11465062. 5: Jiang W, Liu L, Wang M, Li X, Zhou T, Hou X, Qiao L, Chen C, Zuo D, Liu J, Ren L. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. Cell Mol Life Sci. 2024 Oct 5;81(1):417. doi: 10.1007/s00018-024-05442-6. PMID: 39367978; PMCID: PMC11455850. 6: Hou Y, Zak J, Shi Y, Pratumchai I, Dinner B, Wang W, Qin K, Weber EW, Teijaro JR, Wu P. Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy. Cancer Immunol Res. 2024 Oct 4. doi: 10.1158/2326-6066.CIR-24-0089. Epub ahead of print. PMID: 39365901. 7: Maruyama D. [Current standard treatments and future outlook for follicular lymphoma]. Rinsho Ketsueki. 2024;65(9):1004-1011. Japanese. doi: 10.11406/rinketsu.65.1004. PMID: 39358254. 8: Fu M, Wang Y, Ge M, Hu C, Xiao Y, Ma Y, Gou S. Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway. Bioorg Med Chem Lett. 2024 Nov 15;113:129968. doi: 10.1016/j.bmcl.2024.129968. Epub 2024 Sep 16. PMID: 39293534. 9: Schiano C, Trama U, Coscioni E, Infante T, Coppola A, de Nigris F, Napoli C. Epitranscriptome: A Novel Regulatory Layer during Atherosclerosis Progression. Curr Med Chem. 2024 Aug 30. doi: 10.2174/0109298673322775240822051304. Epub ahead of print. PMID: 39219432. 10: Kumar EA, Korfi K, Bewicke-Copley F, Close K, Heward J, Witzig T, Leukam M, Ansell S, Scott J, Clear A, Efeyan A, Green M, Siebert R, Peck B, Calaminici M, Wang J, Smith S, Novak A, Fitzgibbon J, Okosun J. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. Br J Haematol. 2024 Nov;205(5):1804-1809. doi: 10.1111/bjh.19671. Epub 2024 Aug 26. PMID: 39188028. 11: Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S. Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. Int J Hematol. 2024 Nov;120(5):621-630. doi: 10.1007/s12185-024-03834-9. Epub 2024 Aug 23. PMID: 39179948; PMCID: PMC11513718. 12: Hsu C, Konner JA, Gounder MM. Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword. N Engl J Med. 2024 Aug 22;391(8):770-772. doi: 10.1056/NEJMc2407971. PMID: 39167815. 13: Taheri N, Choi EL, Nguyen VTT, Zhang Y, Huynh NM, Kellogg TA, van Wijnen AJ, Ordog T, Hayashi Y. Inhibition of EZH2 Reduces Aging-Related Decline in Interstitial Cells of Cajal of the Mouse Stomach. Cell Mol Gastroenterol Hepatol. 2024;18(4):101376. doi: 10.1016/j.jcmgh.2024.101376. Epub 2024 Jul 3. PMID: 38969206; PMCID: PMC11359770. 14: Fu F, Zhang Y, Shen H. [Advances in Targeted Therapy for Malignant Pleural Mesothelioma]. Zhongguo Fei Ai Za Zhi. 2024 May 20;27(5):391-398. Chinese. doi: 10.3779/j.issn.1009-3419.2024.102.18. PMID: 38880927; PMCID: PMC11183316. 15: Rajput N, Jadav T, Sengupta P. Identification and characterization of the rat in-vivo and in-vitro metabolites of tazemetostat using LC-QTOF-MS. Food Chem Toxicol. 2024 Aug;190:114785. doi: 10.1016/j.fct.2024.114785. Epub 2024 Jun 6. PMID: 38849047. 16: Buteyn NJ, Burke CG, Sartori VJ, Deering-Gardner E, DeBruine ZJ, Kamarudin D, Chandler DP, Monovich AC, Perez MW, Yi JS, Ries RE, Alonzo TA, Ryan RJ, Meshinchi S, Triche TJ Jr. EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion. bioRxiv [Preprint]. 2024 Jun 25:2024.05.14.594150. doi: 10.1101/2024.05.14.594150. PMID: 38798454; PMCID: PMC11118270. 17: O'Donnell E, Muñoz M, Davis R, Randall RL, Tepper C, Carr-Ascher J. Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target. bioRxiv [Preprint]. 2024 May 14:2024.05.14.594060. doi: 10.1101/2024.05.14.594060. PMID: 38798385; PMCID: PMC11118861. 18: Orleni M, Parise RA, Holleran JL, Amengual JE, Feng Y, Synold T, Beumer JH. Quantitation of tazemetostat in human plasma using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2024 Jul;38(7):e5903. doi: 10.1002/bmc.5903. Epub 2024 May 23. PMID: 38783541. 19: Kazansky Y, Mueller HS, Cameron D, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Mundi PS, Kuwahara Y, Somwar R, Qu R, Califano A, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas. bioRxiv [Preprint]. 2024 May 6:2024.05.03.592420. doi: 10.1101/2024.05.03.592420. PMID: 38766189; PMCID: PMC11100591. 20: Matasar M, Sanchez Alvarez J, Parisé H, Zuk E, Di Maio D, Shapouri S, Kim E, Lin SW. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2024 Jan-Dec;27(1):766-776. doi: 10.1080/13696998.2024.2352820. Epub 2024 Jun 6. PMID: 38712895.